scout
|Videos|July 18, 2014

Return of Interferon in RCC

For High-Definition, Click

Although not commonly used, interferon could soon be undergoing a renaissance for patients with renal cell carcinoma (RCC), believes Nicholas J. Vogelzang, MD. This treatment is still commonly used in Japan and will soon be combined with PD-1 inhibitors in clinical trials. It seems likely that interferon will once again have a role for patients with RCC, Vogelzang suggests.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME